|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83.49 USD | -0.04% |
|
-8.60% | +7.30% |
| 03-03 | UBS Adjusts Price Target on Kymera Therapeutics to $128 From $90, Maintains Buy Rating | MT |
| 02-26 | Kymera Therapeutics, Inc., Q4 2025 Earnings Call, Feb 26, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 6.82B | - | ||||
| 45.49B | |||||
| 33.41B | |||||
| 31.32B | |||||
| 29.29B | |||||
| 19.5B | - | - | - | - | - |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition